Medtronic Submits IDE to FDA for U.S. Randomized Clinical Trial for Uncontrolled Hypertension Patients with Systolic Blood Pressure Between 140-160 mm Hg

[at noodls] – IDE Submission for Symplicity HTN-4 Expands the Indicated Patient Population and Builds upon Medtronic’s Rigorous Global Clinical Trial Program for Hypertension Treatment MINNEAPOLIS – March 7, 2013 – … more

View todays social media effects on MDT

View the latest stocks trending across Twitter. Click to view dashboard

See who Medtronic is hiring next, click here to view